Dual‐Phase Efficacy of a Repair Cream Containing Dexpanthenol, Recombinant Human Fibronectin Peptide, and Coreopsis tinctoria Extract Following 1565‐Nm Non‐Ablative Fractional Laser in Sensitive Skin: A Randomized Split‐Face Trial

ABSTRACT Background The 1565‐nm non‐ablative fractional laser (NAFL) induces dermal thermal damage while preserving epidermal integrity, producing immediate postoperative erythema, edema, and barrier disruption. The ultra‐early 0–2‐h recovery window remains poorly characterized by quantitative data, and medium‐term post‐laser trials lack objective dermal endpoints. Objective To evaluate the dual‐phase efficacy and safety of a repair cream containing dexpanthenol, recombinant human fibronectin peptide (rhFNP), and Coreopsis tinctoria extract following 1565‐nm NAFL treatment. Methods A single‐center, randomized, investigator‐blind, split‐face trial enrolled 33 females with sensitive and barrier‐impaired skin. Participants received full‐face 1565‐nm NAFL. For short‐term assessment, one side received the repair cream while the contralateral side remained untreated. For medium‐term evaluation, sides were randomized to the repair cream or the standard‐care comparator. Endpoints included transepidermal water loss (TEWL), hydration, erythema index (EI), blood perfusion, surface temperature, and dermal thickness/density. Results Within 2 h, the repair cream reduced TEWL by 4.63% at 30 s and 3.94% at 2 h, increased hydration by 89.76% at 30 s, lowered EI by 5.96%, perfusion by 17.85%, and surface temperature by 2.15%, all at 10 min (each p < 0.001). Over 14 days, TEWL decreased by 4.34% versus 1.12% on the comparator side, with skin thickness increasing by 12.67% versus 6.62% and density by 17.70% versus 0.15%. No adverse events occurred. Conclusion This repair cream mitigates acute inflammatory responses within 2 h and is associated with favorable early changes in ultrasonographically assessed dermal parameters over 14 days, offering a post‐NAFL care option for sensitive skin populations.